.svg){kind=small}
Phase I trials have evolvedEU Legislative developments have redefined the boundaries of Phase I and opened a new era of opportunity to expedite compounds through the Early Phases. Pharmacology and patient studies can now be integrated or work independently of one another. Clinical & therapeutic innovations now enable Early Phase research to deliver more dynamic and insightful studies, maximizing the probability of a compound reaching the later Phases. We have put together the definitive one-day seminar to explore the new boundaries of Phase I.Click here for more information
-min.jpg)
.jpg)
Latest news
Richmond Pharmacology Appoints Patrick Ramiah as Director of Clinical Project Delivery & Operational Excellence
September 1, 2025
Richmond Pharmacology is delighted to announce the promotion of Patrick Ramiah to the role of Director of Clinical Project Delivery & Operational Excellence, effective from 1 September 2025.
Read moreEvents
JSCPT 2025
5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event
